Tirzepatide is a synthetic peptide designed as a dual agonist of GIP and GLP-1 receptors, integrating two incretin pathways within one molecule. It is a prominent compound in endocrine and metabolism research due to its strong receptor-mediated effects on glucose and appetite-related signalling.
Tirzepatide is a synthetic peptide designed as a dual agonist of GIP and GLP-1 receptors, integrating two incretin pathways within one molecule. It is a prominent compound in endocrine and metabolism research due to its strong receptor-mediated effects on glucose and appetite-related signalling.
Studies commonly evaluate tirzepatide by tracking incretin receptor signalling, glucose-dependent insulin secretion markers, gastric emptying dynamics, and central appetite regulation pathways. Research also examines downstream impacts on metabolic biomarkers—including insulin sensitivity indicators and lipid- related markers—to understand how dual incretin agonism modifies systemic energy balance signalling.
